Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract

February 23, 2018
Basilea Pharmaceutica International Ltd.

Basel, Switzerland, February 23, 2018 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has commenced enrollment in the first of its two planned clinical phase 3 registration studies of the antibiotic ceftobiprole...